| Identification | Back Directory | [Name]
(3aR)-3,3aβ,4,5,6,6aβ-Hexahydro-5α-hydroxy-4β-[(1E,3S)-3-hydroxy-3-(4α-propylcyclohexan-1α-yl)-1-propenyl]cyclopenta[b]pyrrole-2-pentanoic acid methyl ester | [CAS]
101758-79-6 | [Synonyms]
(3aR)-3,3aβ,4,5,6,6aβ-Hexahydro-5α-hydroxy-4β-[(1E,3S)-3-hydroxy-3-(4α-propylcyclohexan-1α-yl)-1-propenyl]cyclopenta[b]pyrrole-2-pentanoic acid methyl ester | [Molecular Formula]
C25H41NO4 | [MDL Number]
MFCD30738673 | [MOL File]
101758-79-6.mol | [Molecular Weight]
419.6 |
| Hazard Information | Back Directory | [Description]
OP-2507 is a prostacyclin agonist potentially for the treatment of hepatic insufficiency and hypertension. | [Uses]
OP-2507 is a prostacyclin analog. OP-2507 can increase brain glucose levels in mice, suppress the breakdown of energy metabolism under hypoxic conditions, and has a protective effect against changes in cyclic nucleotides in hypoxic brain tissue (specifically, an increase in cyclic AMP and a decrease in cyclic GMP). OP-2507 provides protective effects against brain hypoxia and edema[1]. | [References]
[1] Masuda Y, et al. Protective effect of a new prostacyclin analogue OP-2507 against cerebral anoxia and edema in experimental animals. Eur J Pharmacol. 1986 Apr 29;123(3):335-44. DOI:10.1016/0014-2999(86)90706-5 |
|
|